Effects of MPL in a variety of human cancer cell lines In conjunction with our recent canine program to optimise the reformulation of monepantel and prepare for the canine clinical trial protocol, PharmAust has also been working with Dr Doug Fairlie PhD at the Olivia Newton John Cancer Centre in Melbourne to further analyse tumours for which MPL should be preferentially used. This work has independently confirmed that MPL is effective at killing selected tumour cells. This data, together with the data generated from the trial for canines with cancer,will form a basis to commence clinical trials in humans
Ann: Appendix 4C & Company Update - June 18, page-2
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 20.5¢ | $106.7K | 516.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24033 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 55077 | 2 |
View Market Depth
| Last trade - 15.22pm 22/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |